Orchard Therapeutics (NASDAQ:ORTX) Q3 2019 Earnings Conference Call Transcript
Nov 06, 2019 • 04:30 pm ET
Ladies and gentlemen, thank you for standing by and welcome to the Orchard Therapeutics Third Quarter 2019 Investor Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Renee Leck, Director of Investor Relations. Thank you, please go ahead, madam.
Thanks, operator. Good afternoon, everyone, and welcome to Orchard's third quarter 2019 investor update. You can access slides for today's call by going to the Investors section of our website orchard-tx.com.
Before we get started, I'd like to remind everyone that statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risk factors and uncertainties, including those set forth in the most recent Form 20-F filed with the SEC and any other filings that we may make. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.
With that, I'll turn the call over to our President and CEO, Mark Rothera.
Thanks, Renee. Good afternoon and welcome. I hope you're all enjoying the annual excitement with the release of the ASH abstracts this morning, which included several from Orchard's gene therapy portfolio. The purpose for today's call is twofold. Firstly, we'd like to bring you up to date on our progress executing against our corporate priorities, while reviewing some recent business highlights. And secondly, we'll set the stage for the data releases from our registrational programs in ADA-SCID and Wiskott-Aldrich Syndrome that have been accepted at ASH in December.
Our CSO, Bobby Gaspar, will cover the second topic in more detail after my opening remarks. Then Frank Thomas, Orchard's CFO will spend some time reviewing the third quarter financial results and outlook. I'll return to close with a discussion of our commercial strategy as we prepare for multiple filings, potential approvals and product launches in 2020 and beyond.
Before I highlight the data sets coming up at ASH, I'd like to take a step back to remind those of you who are newer to the story, who we are and to recap the tremendous progress we've made this year. Orchard is a pure play gene therapy company, with a focused approach on singular mission to deliver transformative and potentially curative therapies to patients, often children, suffering from life-threatening rare genetic diseases around the world. Our expertise lies in developing ex-vivo autologous hematopoietic stem cell or HSC gene therapies. A platform approach that is demonstrated clinical proof of concept in five different diseases in our portfolio so far. As a company, we view the term patient as a temporary label and see the opportunity for lifelong benefits, including the